Compound ID | 85
Class: Beta-lactam
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against infections caused by multidrug-resistant Gram-negatives |
| Description: | A carbapenem |
| Institute where first reported: | AstraZeneca (UK) + FOB Synthesis, Inc (USA) |
| Year first mentioned: | 2014 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
| External links: | |
| Citations: |
|